2 recruiting, 1 terminated, 1 withdrawn. 4 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Recruiting 2, Terminated 1, Withdrawn 1 |
| Phase 2 | 3 | Recruiting 2, Terminated 1 |
Follow Thyroid Carcinoma, Anaplastic: new trials by email Literature Review of Thyroid Carcinoma, Anaplastic trials Research Report on Thyroid Carcinoma, Anaplastic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. Dabrafenib, Trametinib - Haematological Malignancy, Malignant Neoplasm | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2026-04-01 | 2026-08-17 |
| DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. Vemurafenib, Cobimetinib - Haematological Malignancy, Melanoma | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2023-03-01 | 2025-11-24 |
| Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer Fosbretabulin + paclitaxel + carboplatin, Placebo + paclitaxel + carboplatin - Anaplastic Thyroid Cancer | Phase 3 | Withdrawn | Mateon Therapeutics | 2015-03-01 | 2014-05-01 | |
| Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer CA4P, paclitaxel, carboplatin - Anaplastic Thyroid Cancer | Phase 2 / Phase 3 | Terminated | Mateon Therapeutics | 80 | 2007-08-01 | 2014-06-09 |
Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Erdheim-Chester Disease (2) · Glioma (2) · Hematologic Neoplasms (2) · Laryngeal Neoplasms (2) · Multiple Myeloma (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Ovarian Neoplasms (2) · Thyroid Cancer, Papillary (2) · Thyroid Neoplasms (2) · Gastrointestinal Neoplasms (1)
Carcinoma (4) · Endocrine Gland Neoplasms (4) · Endocrine System Diseases (4) · Neoplasms, Glandular and Epithelial (4) · Thyroid Diseases (4) · Head and Neck Neoplasms (3) · Adenocarcinoma (2) · Adenocarcinoma, Papillary (2) · Adnexal Diseases (2) · Blood Protein Disorders (2) · Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Cardiovascular Diseases (2) · Colonic Diseases (2) · Digestive System Diseases (2)
Carboplatin (2) · Paclitaxel (2) · combretastatin (2) · fosbretabulin (2) · Vemurafenib (1) · cobimetinib (1) · dabrafenib (1) · trametinib (1)
Cancer Research UK (2) · Mateon Therapeutics (2)
United Kingdom (3) · Belarus (1) · Bulgaria (1) · Egypt (1) · India (1) · Israel (1) · Italy (1) · Poland (1) · Romania (1) · Russia (1) · Ukraine (1) · United States (1)
Julie A Sosa, MD (1) · Julie A. Sosa, MD, FACS (1) · Lisa Licitra, MD (1) · Marcia Brose, MD, PhD (1) · Matthew Krebs (1) · Matthew Krebs, Dr (1)